
19/04/2021

Press Releases

Reed Sinopharm Exhibitions acquires majority stake in the China Hospital Construction Conference

By RX

[Digital and Data](#) [Events](#)



Reed Sinopharm Exhibitions, the joint venture between RX Global and the Sinopharm Group, has signed a definitive agreement to acquire a majority stake in the China Hospital Construction Conference (CHCC).

CHCC is Asia's leading event in comprehensive and innovative solutions for Hospital Design, Build and Management. Launched in 1999, the event spans over 100,000sqm featuring over 600 exhibitors and 16 themed displays. In addition to the trade show exhibition, CHCC also produces over 80 conference sessions and offers excellent learning opportunities, knowledge sharing and information exchange for over 10,000 hospital designers and managers every year.

Commenting on the acquisition, Hugh Jones, CEO of RX Global, said: "We have been very impressed by the CHCC team's continuous drive to innovate and build a broad platform for the coordinated development of the whole industry. I firmly believe that in adding the CHCC brand to Reed Sinopharm Exhibitions' health sector portfolio, we will bring our expertise in face-to-face and virtual experiences, global reach and resources, to bear on CHCC's members, stakeholders, academics and industry leaders, ensuring growth, development and value for all our partners."

Michael Cheng, CEO of RX Global China, said: "I'm excited to welcome the CHCC team to the family and look forward to working together with Reed Sinopharm Exhibitions and our new partner to enhance this leading show and adding value to the CHCC audience."

The 22nd CHCC will take place at Shenzhen World Exhibition & Convention Center from 19th to 21st June, 2021. Thousands of hospital construction decision-makers and more than 800 outstanding enterprises will gather together to discuss the construction of the next generation hospitals.

ENDS

About Reed Sinopharm Exhibitions

Reed Sinopharm Exhibitions is one of the most renowned event organisers dedicated to pharmaceutical and medical sectors in China. The company is a joint venture between China National Pharmaceutical Group Corporation (Sinopharm) – the largest medical and healthcare group in China, and RX Global – one of the world's leading event organisers. RSE runs a portfolio of 30 highly recognized events, which serve the entire value chain of healthcare with an extended market reach into education and scientific research sectors. www.reed-sinopharm.com

About RX Global Global

RX Global is a leading global events business. It combines face-to-face with data and digital tools to help customers learn about markets, source products and complete transactions at over 400 events in 22 countries across 43 industry sectors, attracting more than 7 million participants. Our events leverage industry expertise, large data sets and technology to enable our customers to connect face-to-face or digitally and generate billions of dollars of revenues for the economic development of local markets and national economies around the world. RX Global is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.reedexhibitions.com

About RELX

RELX is a global provider of information-based analytics and decision tools for professional and business customers. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs over 33,000 people, of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £37.4bn, €43.3bn, \$51.8bn.*

*Note: Current market capitalisation can be found at <https://www.relx.com/investors>